TAPISTRY Study: Personalized Immunotherapy and Targeted Treatment for Advanced Solid Tumors

Sponsor: Hoffmann-La Roche

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT04589845

Provider View

This study is exploring personalized treatments for patients with advanced solid tumors that cannot be surgically removed. It uses genetic testing to match patients with specific therapies that target their tumor's unique genetic makeup.

Patient Parameters

Program Overview

The TAPISTRY study is a global research project that aims to find out how safe and effective personalized treatments are for people with advanced solid tumors. These tumors have specific genetic changes or a high number of mutations. Participants will receive a treatment plan based on their genetic test results. The study will continue until the cancer progresses, the treatment is no longer beneficial, side effects become too severe, or the participant or doctor decides to stop.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of advanced solid cancer that cannot be surgically removed or has spread.
  • Have measurable disease according to specific medical criteria.
  • Be in good overall health, with a performance status score appropriate for their age group.
  • Have adequate blood and organ function.
  • Have cancer that has progressed after previous treatment or is untreated with no other options available.
  • Have recovered from any recent cancer treatments.
  • Have a life expectancy of at least 8 weeks.
  • Be able to follow the study procedures.
  • Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control during the study.
  • Men must agree to use effective birth control methods.
  • Meet any additional criteria specific to their treatment group.

Exclusion Criteria

  • Currently participating in another clinical trial.
  • Have had any cancer treatment within 2 weeks before starting the study.
  • Have had whole brain radiotherapy within 14 days or stereotactic radiosurgery within 7 days before starting the study.
  • Are pregnant, breastfeeding, or planning to become pregnant during the study.
  • Have a serious medical condition or abnormal lab results that could affect their safety or the study results.
  • Have not fully recovered from any recent surgery.
  • Have significant heart disease or recent heart attack or stroke.
  • Have another active cancer within the last 5 years that could interfere with the study.
  • Must not meet any additional exclusion criteria specific to their treatment group.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.